Page 1 of 8, showing 50 records out of 368 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
4770. Labrie, F. (2011) Blockade of all sources of androgens is key to optimal treatment at all stages of prostate cancer: Observations made in the 1980's are the basis of current progress in new drug development. Prostate Cancer Communication – Choices, 27: 3-10. |
Prostate Cancer |
2011 |
|
4763. Labrie, F. (2011) Editorial: The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab. 6:313-316. |
Prostate Cancer |
2011 |
|
4758. Yamana, K., Labrie, F., Luu-The, V (2010) Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride, Horm Mol Biol Clin Invest. 2:293-299. |
Prostate Cancer |
2010 |
|
4750. Labrie, F. (2010) Editorial Comment: Kaliks RA et al. Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer. International Braz J Urol. 36: 306-307 |
Prostate Cancer |
2010 |
|
4753. Labrie, F. (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nature Reviews. 8: 73-80 |
Prostate Cancer |
2011 |
|
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. |
Prostate Cancer |
2011 |
|
4735. Labrie, F. (2010) Hormonal therapy of prostate cancer. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff De, eds. Pathological Situations and Diseases, Progress in Brain Research. Elsevier. Chapter 14, Vol. 182 321-341. |
Prostate Cancer |
2010 |
|
5. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Prostate Cancer |
2007 |
|
91. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. |
Prostate Cancer |
1996 |
|
155. Bélanger, A., Brochu, M., Lacoste, D., Noel, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., Couture, J. (1991) Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 40: 593-598. |
Prostate Cancer |
1991 |
|
121. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
Prostate Cancer |
1994 |
|
131. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. |
Prostate Cancer |
1993 |
|
108. Bélanger, A., Van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T.A., Lihua, H., Poppe, I., Labrie, F. (1995) Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate, 27: 187-197. |
Prostate Cancer |
1995 |
|
178. Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., Monfette, G. (1989) Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem., 32: 695-698. |
Prostate Cancer |
1989 |
|
164. Bélanger, C., Veilleux, R., Labrie, F. (1990) Stimulatory effects of androgens, estrogens, progestins and dexamethasone on the growth of the LNCaP human prostate cancer cells. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 399-402. |
Prostate Cancer |
1990 |
|
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Prostate Cancer |
1999 |
|
44. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. |
Prostate Cancer |
2000 |
|
15. Candas, B., Labrie, F., Gomez, J.L., Cusan, L., Chevrette, E., Levesque, J., Brousseau, G. (2006) Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol, 175: 510-517. |
Prostate Cancer |
2006 |
|
165. Candas, B., Lacoste, D., Normand, M., Labrie, F. (1990) Model of the distribution and metabolism of the gonadotropin-releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH2(10)]GnRH ethylamide in man. J. Clin. Endocrinol. Metab. 70: 1046-1054. |
Prostate Cancer |
1990 |
|
6. Cantin, L., Faucher, F., Couture, J.F., de Jésus, K.P., Legrand, P., Ciobanu, L., Fréchette, Y., Labrecque, R., Singh, S.M., Labrie, F., Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem, 282: 30910-9. |
Prostate Cancer |
2007 |
|
92. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. |
Prostate Cancer |
1996 |
|
93. Chen, C., Poulin, R., Labrie, F. (1996) Large Shionogi tumors lose their responsiveness to Flutamide treatment. J. Steroid Biochem. Mol. Biol., 58: 489-494. |
Prostate Cancer |
1996 |
|
109. Chen, C., Puy, L.A., Simard, J., Li, X., Singh, S.M., Labrie, F. (1995) Local and systemic reduction by topical Finasteride or Flutamide on hamster flank organ size and enzyme activity. J. Invest. Dermatol., 105: 678-682. |
Prostate Cancer |
1995 |
|
36. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. |
Prostate Cancer |
2001 |
|
94. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. |
Prostate Cancer |
1996 |
|
122. Cusan, L., Gomez, J.L., Dupont, A., Diamond, P., Lemay, M., Moore, S., Labrie, F. (1994) Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate, 24: 257-261. |
Prostate Cancer |
1994 |
|
156. de Launoit, Y., Veilleux, R., Dufour, M., Simard, J., Labrie, F. (1991) Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res., 51: 5165-5170. |
Prostate Cancer |
1991 |
|
95. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. |
Prostate Cancer |
1996 |
|
166. Dupont, A., Boucher, H., Cusan, L., Lacourcière, Y., Emond, J., Labrie, F. (1990) Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with Flutamide and castration. Eur. J. Cancer, 26: 770-771. |
Prostate Cancer |
1990 |
|
157. Dupont, A., Cusan, L., Gomez, J.-L., Thibeault, M.M., Tremblay, M., Labrie, F. (1991) Prostatic specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J. Urol., 146: 1064-1068. |
Prostate Cancer |
1991 |
|
132. Dupont, A., Cusan, L., Gomez, J.L., Koutsilieris, M., Suburu, R., Emond, J., Labrie, F. (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol., 72: 629-634. |
Prostate Cancer |
1993 |
|
133. Dupont, A., Gomez, J.L., Cusan, L., Koutsilieris, M., Labrie, F. (1993) Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913. |
Prostate Cancer |
1993 |
|
179. Dupont, A., Labrie, F., Manhès, G., Bergeron, N., Cusan, L., Pinault, S., Bélanger, A., Boucher, M., Lacourcière, Y., Emond, J. (1989) Combination therapy with Flutamide and the LHRH agonist [D-Trp6, des-Gly-NH210]LHRH ethylamide in stage C prostatic carcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 89-102. |
Prostate Cancer |
1989 |
|
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Prostate Cancer |
1999 |
|
45. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. |
Prostate Cancer |
2000 |
|
180. Emond, J., Dupont, A., Cusan, L., Bergeron, N., Manhès, G., Labrie, F. (1989) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) as an alternative to transurethral resection of the prostate for urinary retention in prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, pp 103-108. |
Prostate Cancer |
1989 |
|
37. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. |
Prostate Cancer |
2001 |
|
147. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Suburu, E.R., Lemay, M., Labrie, F. (1992) Incidence of liver toxicity associated with the use of Flutamide in prostate cancer patients. Am. J. Med., 92: 465-470. |
Prostate Cancer |
1992 |
|
148. Gomez, J.L., Dupont, A., Cusan, L., Tremblay, M., Tremblay, M., Labrie, F. (1992) Simultaneous liver and lung toxicity related to the non-steroidal antiandrogen Nilutamide (Anandron): a case report. Am. J. Med., 92: 563-566. |
Prostate Cancer |
1992 |
|
58. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. |
Prostate Cancer |
1999 |
|
123. Koutsilieris, M., Dupont, A., Gomez, J.L., Cusan, L., Suburu, R., Diamond, P., Labrie, F. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal therapy (GnRH-A plus Flutamide). Anticancer Res., 14: 627-634. |
Prostate Cancer |
1994 |
|
4707. Lévesque, M.H., El-Alfy, M., Cusan, L., Labrie, F. (2009) Androgen receptor as a potential sign of prostate cancer metastasis, The Prostate, 69: 1704-1711. |
Prostate Cancer |
2009 |
|
96. Labrie, C., Flamand, M., Bélanger, A., Labrie, F. (1996) High bioavailability of DHEA administered percutaneously in the rat. J. Endocrinol., 150: S107-S118. |
Prostate Cancer |
1996 |
|
167. Labrie, C., Simard, J., Poulin, M., Bélanger, A., Pelletier, G., Labrie, F. (1990) Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 392-394. |
Prostate Cancer |
1990 |
|
168. Labrie, C., Simard, J., Zhao, H.F., Bélanger, A., Pelletier, G., Labrie, F. (1990) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F. eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 395-398. |
Prostate Cancer |
1990 |
|
169. Labrie, C., Simard, J., Zhao, H.F., Pelletier, G., Labrie, F. (1990) Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol. Cell. Endocrinol., 68: 169-179. |
Prostate Cancer |
1990 |
|
158. Labrie, C., Trudel, C., Li, S., Martel, C., Couët, J., Labrie, F. (1991) Combination of an antiandrogen and a 5a-reductase inhibitor: a further step towards total androgen blockade? Endocrinology, 129: 566-568. |
Prostate Cancer |
1991 |
|
170. Labrie, F. (1990) Goserelin study criticized. Oncology Times, 10: 18-19. |
Prostate Cancer |
1990 |
|
171. Labrie, F. (1990) Peripheral tissues are important sites of sex steroid formation in the human: a new field of endocrinology which extends from gene structure to therapy that prolongs life in prostate cancer. Physiol Canada, 13th Sarrazin Lecture, 21: 66-99. |
Prostate Cancer |
1990 |
|
159. Labrie, F. (1991) Endocrine therapy for prostate cancer, in: Strauss, J.F., ed. Endocrinology and Metabolism Clinics of North America, Philadelphia, W.B. Saunders, pp 845-872. |
Prostate Cancer |
1991 |